newsfilter
← Latest News
GlobeNewswire·

Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Q4 2025 net product revenue for ZORYVE® (roflumilast) was $127.5 million, an 84% increase compared to Q4 2024, and a 29% increase compared to Q3 2025Full year 2025 net product revenue for ZORYVE was $372.1 million,